Tradestie Institutional Equity Comparison Engine

STLN vs ICU โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ICU Overall Edge

ICU Captures Institutional Edge (2โ€“1 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to SeaStar Medical Holding Corporation Common Stock (ICU) driven by superior Growth & Margin, Momentum & Technical while STLN counters with relative strength in Options & Structure. Fundamentally, STLN trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ICU at N/M Forward P/E and -816.6% operating margin (+82.0% YoY). In options structure, STLN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ICU sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
STLN N/M vs ICU N/M Fwd P/E
Growth & Margin Winner ICU
Op Margin N/A vs -816.6% ยท YoY N/A vs +82.0%
Momentum & Technical Winner ICU
1Y -42.0% vs +200.4% ยท 52W Pos 1% vs 14%
Options & Structure Winner STLN
UNCLASSIFIED (N/A IV) vs BREAKDOWN (N/A IV)
STLN US Equity
STLN
Institutional Equity
$3.00
-5.66% 1D
Market Cap N/A
1M Return -56.58%
1Y Return -41.97%
Forward P/E N/M
Unified AI Score
46.6 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 55.0
ICU NASDAQ
SeaStar Medical Holding Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.94
-10.95% 1D
Market Cap $5.6M
1M Return -67.19%
1Y Return +200.45%
Forward P/E N/M
Unified AI Score
49.6 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: STLN -41.97% ICU +200.45% Spread: +28.72 pp (STLN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
STLN TTM Op. Margin: N/A ICU TTM Op. Margin: -816.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on STLN vs ICU. Trailing 12-month operating profitability (STLN N/A vs ICU -816.6%) and valuation multiples (STLN N/M vs ICU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: STLN (1) vs ICU (7)
Institutional Metric STLN ICU Criterion Row Winner
Market Capitalization Scale N/A $5.6M Larger Scale ICU
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +82.0% Higher Growth ICU
Operating Margin (TTM) Profitability N/A -816.6% Higher Margin ICU
Net Profit Margin Profitability N/A 0.0% Higher Margin ICU
Return on Equity (ROE) Capital Efficiency N/A -356.9% Higher ROE ICU
52-Week Range Position Momentum 1% ($3โ€“$7) 14% ($0โ€“$5) Stronger Trend ICU
Beta / 30D Volatility Risk Regime 1.42ฮฒ ยท 175% Vol 1.41ฮฒ ยท 216% Vol Lower Realized Risk STLN
Unified Institutional Score Composite Signal 46.6 / 100 (HOLD) 49.6 / 100 (HOLD) Higher Composite ICU

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full STLN vs ICU Buy Guide
STLN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live STLN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ICU BREAKDOWN
133d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ICU Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither STLN nor ICU registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.